JING DI

Dr. JING DI

Pathology, University of Kentucky HealthCare, Lexington, Kentucky, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

28 November 2024 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
JING DIJING DI
JING DI
TSTao Sheng
Tao Sheng
RARanjana Arora
Ranjana Arora
JSJennifer Stocks-Candelaria
Jennifer Stocks-Candelaria
SWSainan Wei
Sainan Wei
SZShulin Zhang
Shulin Zhang

23 May 2022 in Human Pathology Reports
Verified
Journal Article
Open access
JING DIJING DI
JING DI
SQShadi A. Qasem
Shadi A. Qasem

3 March 2023 in Genes
Verified
Journal Article
Open access
PDF file
JING DIJING DI
JING DI
LYLeonard Yenwongfai
Leonard Yenwongfai
HRHillary T. Rieger
Hillary T. Rieger
SZShulin Zhang
Shulin Zhang
Sainan WeiSainan Wei
Sainan Wei
Chromosome 4p deletions can lead to two distinct phenotypic outcomes: Wolf-–Hirschhorn syndrome (a terminal deletion at 4p16.3) and less frequently reported proximal interstitial deletions (4p11-p16). Proximal 4p interstitial deletions can result in mild to moderate intellectual disability, facial dysmorphisms, and a tall thin body habitus. To date, only 35 cases of proximal 4p interstitial deletions have been reported, and only two of these cases have been familial. The critical region for this syndrome has been narrowed down to 4p15.33-15.2, but the underlying causative genes remain unclear. In this study, we report the case of a 3-year-old female with failure to thrive, developmental and motor delays, and morphological features. The mother also had a 4p15.2-p14 deletion, and the proband was found to have a 13.4-Mb 4p15.2-p14 deletion by chromosome microarray analysis. The deleted region encompasses 16 genes, five of which have a high likelihood of contributing to the phenotype: PPARGC1A, DHX15, RBPJ, STIM2, and PCDH7. These findings suggest that multiple genes are involved in this rare proximal 4p interstitial deletion syndrome. This case highlights the need for healthcare providers to be aware of proximal 4p interstitial deletions and the potential phenotypic manifestations.

1 August 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
JING DIJING DI
JING DI
AAAli Alhaidary
Ali Alhaidary
CWChi Wang
Chi Wang
JLJinge Liu
Jinge Liu
Sainan WeiSainan Wei
Sainan Wei
TBThérèse Bocklage
Thérèse Bocklage
Nuclear Protein in Testis (NUT)-rearranged tumors comprise predominantly NUT carcinoma but also include certain lymphomas, leukemias, skin appendage tumors, and sarcomas. Although histologically diverse, all are genetically identified by oncogenic rearrangement in the NUTM1 gene. Many fusion partners occur, and NSD3 is NUT carcinoma’s third most common partner. Herein, we present a case of a 26-year-old man with an NSD3::NUTM1 fusion sarcoma. The patient presented at the age of 13 months with a scalp nodule. Over the next 24 years, he experienced five local recurrences and ultimately expired of a rapidly progressive recurrence. His treatment included surgical resections, radiation, and various chemotherapies. Deceptively, the clinical presentation and histopathology aligned with a malignant peripheral nerve sheath tumor, a diagnosis rendered at initial resection with concurrence by a national soft tissue tumor expert. The patient’s exceptionally long survival could be due to NSD3 as the fusion partner, aided by the initial small tumor size and young patient age. Thus, this case expands NUT fusion sarcomas’ histologic and immunohistochemical profile to include mimicking a malignant peripheral nerve sheath tumor (MPNST). Additionally, it indicates that the NSD3::NUTM1 fusion can drive sarcoma genesis.

20 July 2024 in Cureus
Verified
Journal Article
Open access
PDF file
JING DIJING DI
JING DI
SWSainan Wei
Sainan Wei
AJAmie Jackson
Amie Jackson
RMReinhold Munker
Reinhold Munker
MKMelissa V. Kesler
Melissa V. Kesler
We report a distinctive case of sequential lymphomas in a 72-year-old male, initially diagnosed with Epstein-Barr virus (EBV)-positive rectal classic Hodgkin lymphoma (cHL), followed by the development of diffuse large B cell lymphoma (DLBCL) in the lung. This rare progression underscores the complexity of lymphomas associated with EBV infection and their unpredictable clinical courses. The patient's journey began with symptoms of intractable diarrhea, low appetite, and significant weight loss, leading to the diagnosis of stage 4B cHL, managed initially with brentuximab/doxorubicin, vinblastine, dacarbazine (AVD) chemotherapy. Despite a partial response, surveillance identified a transition to DLBCL, marked by new pulmonary lesions. This case highlights the clinical and diagnostic challenges in managing sequential lymphomas, emphasizing the role of EBV in lymphomagenesis and the potential for clonal evolution from a common precursor cell. The therapeutic approach evolved from targeted chemotherapy to consideration of advanced treatments such as autologous stem cell transplant and chimeric antigen receptor (CAR) T-cell therapy, reflecting the aggressive nature and poor prognosis of the disease. This case contributes to our understanding of the EBV's impact on lymphoma progression and underscores the need for vigilant monitoring and adaptive treatment strategies in similar clinical scenarios.